Difference between revisions of "Medroxyprogesterone acetate (MPA)"
Jump to navigation
Jump to search
m |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
*[[Renal cell carcinoma - historical|Renal cell carcinoma]] | *[[Renal cell carcinoma - historical|Renal cell carcinoma]] | ||
| + | ==History of changes in FDA indication== | ||
| + | *1959-06-18: Initial approval | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*1959-08-20: EURD | *1959-08-20: EURD | ||
| Line 18: | Line 20: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
| − | [[Category: | + | [[Category:Progestins]] |
[[Category:Endometrial cancer medications]] | [[Category:Endometrial cancer medications]] | ||
Latest revision as of 10:42, 4 July 2023
Diseases for which it is used
Diseases for which it was used
History of changes in FDA indication
- 1959-06-18: Initial approval
History of changes in EMA indication
- 1959-08-20: EURD
Also known as
- Generic names: medroxyprogesterone acetate, MPA
- Brand names: Depo-Provera, Provera